title: Iron deficiency in parkinsonism: region-specific iron dysregulation in Parkinson's disease and multiple system atrophy.
abstract: Alpha synuclein pathology is widespread and found in diverse cell types in multiple system atrophy (MSA) as compared to Parkinson's disease (PD). The reason for this differential distribution is unknown. Regional differences in the distribution of iron are associated with neurodegenerative diseases, and here we characterize the relationship between iron homeostasis proteins and regional concentration, distribution and form of iron in MSA and PD. In PD substantia nigra, tissue iron and expression of the iron export protein ferroportin increased, while the iron storage protein ferritin expression was unchanged. In the basis pontis of MSA cases, increased total iron concentration coupled with a disproportionate increase in ferritin in dysmorphic microglia and a reduction in ferroportin expression. This is supported by isothermal remanent magnetisation evidence consistent with elevated concentrations of ferritin-bound iron in MSA basis pontis. Conventional opinion holds that excess iron is involved in neurodegeneration. Our data support that this may be the case in PD. While region-specific changes in iron are evident in both PD and MSA, the mechanisms of iron dysregulation appear quite distinct, with a failure to export iron from the MSA basis pontis coupling with significant intracellular accumulation of ferritin iron. This pattern also occurs, to a lesser extent, in the MSA putamen. Despite the excess tissue iron, the manner of iron dysregulation in MSA is reminiscent of changes in anemia of chronic disease, and our preliminary data, coupled with the widespread pathology and involvement of multiple cell types, may evidence a deficit in bioavailabile iron.
authors.affiliation: Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, ON, Canada.
authors.forename: Naomi P
authors.initials: NP
authors.lastname: Visanji
authors.forename: Joanna F
authors.initials: JF
authors.lastname: Collingwood
authors.forename: Mary E
authors.initials: ME
authors.lastname: Finnegan
authors.forename: Anurag
authors.initials: A
authors.lastname: Tandon
authors.forename: Emily
authors.initials: E
authors.lastname: House
authors.forename: Lili-Naz
authors.initials: LN
authors.lastname: Hazrati
mesh_terms: D000368:Aged; D001921:Brain / Q000378:metabolism*; D001923:Brain Chemistry; D016022:Case-Control Studies; D027682:Cation Transport Proteins / Q000378:metabolism; D005260:Female; D005293:Ferritins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism*; D000090463:Iron Deficiencies; D060306:Magnetometry / Q000379:methods; D008297:Male; D017628:Microglia / Q000737:chemistry / Q000378:metabolism; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000150:complications / Q000378:metabolism*; D010300:Parkinson Disease / Q000150:complications / Q000378:metabolism*; D013054:Spectrophotometry, Atomic / Q000379:methods; D000098742:Ferroportin
chemical_list: D027682:Cation Transport Proteins; D000098742:Ferroportin; D005293:Ferritins; D007501:Iron
keywords: Parkinson's disease; ferritin; ferroportin; inflammation; iron; multiple system atrophy